The role of epithelial mesenchymal transition markers in thyroid carcinoma progression

Endocrine Pathology

Volumn 24, Issue 4, 2013, Pages 206-212

  Montemayor Garcia, Celina ^a   Hardin, Heather ^a   Guo, Zhenying ^a   Larrain, Carolina ^a   Buehler, Darya ^a   Asioli, Sofia ^b   Chen, Herbert ^a   Lloyd, Ricardo V ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Anaplastic thyroid carcinoma; E Cadherin; Smad7; Thyroid carcinoma; ZEB1

Indexed keywords

CELL MARKER; SMAD7 PROTEIN; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN;

ADULT; AGED; ANAPLASTIC THYROID CANCER; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; E BOX ELEMENT; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; VALIDATION PROCESS;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, PAPILLARY; CELL LINE; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MIDDLE AGED; THYROID GLAND; THYROID NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84888173446     PISSN: 10463976     EISSN: 15590097     Source Type: Journal    
DOI: 10.1007/s12022-013-9272-9     Document Type: Article

References (35)

1. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma, treatment outcome and prognostic factors. Cancer 103:1330-1335, 2005.
2. Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC, Grant CS, Thompson GB, Richards ML, Hay ID, Smallridge RC, Bible KC. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 21:25-30, 2011.
3. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 139:871-890, 2009.
4. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265-273, 2009.
5. Das, S, Becker BN, Hoffmann FM, Mertz JE. Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway. BMC Cell Biol 10:94-112. 2009.
6. Kurahara H Takao S, Maemura K, Mataki Y, Kuwahata T, Maeda K, Ding Q, Sakoda M, Lino S, Ishigami S, Ueno S, Shinchi H, Natsugoe S. Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer. J Surg Oncol 105:655-661, 2012.
7. Moustakas A, Helding CH. Signaling networks guiding epithelial- mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 98:1512-1520, 2007.
8. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 307:1603-1609, 2005.
9. Massague J. TGFB signaling in context. Nat Rev Mol Cell Biol 13:616-30, 2012.
10. Drabsch Y, ten Dijke P. TGF-B signaling and its role in cancer progression and metastasis. Cancer Metastasis Rev 31:553-568, 2012.
11. Katsuno Y, Lamouille S, Derynck R. (2013). TGFB signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25:78-84, 2013.
12. Spaderna S, Schmaljofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A, Hlubek F, Jung A, Strand D, Eger A, Kirchner T, Behrens J, Brabletz T. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 68:537-544, 2008.
13. Hurt EM, Saykally JN, Anose BM, Kalli KR, Sanders MM. Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights. Mol Cell Biochem 318:89-99, 2008.
14. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M, Mikulits W Brabletz T, Strand D, Obrist P, Sommergruber W, Schweifer N, Wernitznig A, Beug H, Foisner R, Eger A. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26:6979-6988, 2007.
15. Aigner K,Descovich L, Mikula M, Sultan A, Dampier B, Bonne S, van Roy F, Mikulits W, Schreiber M, Brabletz T, Sommergruber W, Schweifer N, Werntznig A, Berg H, Foisner R, Eager A. The transcription factor ZEB1(deltaEF) repressed Plakophilin 3 during human cancer progression. FEBS Lett 581:1617-1624, 2007.
16. Braun J, Hoang-Vu C, Dralle H, Huttelmaier S. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene 29:4237-4244, 2010.
17. Hebrant A, Dom G, Deqaele M, Andry G, Tresallet C, Leteurte E, Dumont JE, Maenhaut C. mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. PLoS One 7:e37807, 2012.
18. Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush PS, Asioli S, Chen H, Lloyd RV. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol 26:54-61, 2013.
19. Saiselet M, Floor S, Tarabichi M, Dom G, Hebrant A, van Staveren WGG, Maenhauf C. Thyroid cancer cell lines: an overview. Frontiers in endocrinology 3:1-9, 2012.
20. Salerno P, Garcia-Rostan G, Piccinin S, Bencivenga TC, Di Maro G, Doglioni C, Basolo F, Maetro R, Fusco A, Santor M, Salvatore G. TWIST1 plays a pleotrophic role in determining the anaplastic thyroid carcinoma phenotype. J Clin Endocrinol Metab 96:E772-E781, 2011.
21. Hardy RG, Vincente-Duenas C, Gonzalez-Herrero I, Anderson C, Flores T, Hughes S, Tselepis C, Ross JA, Sanchez-Garcia I. Snail family transcription factors are implicated in thyroid carcinogenesis. Am J Patho 171:1037-1046, 2007.
22. Liu J Brown RE. Immunohistochemical detection of epithelial mesenchymal transition associated with stemness phenotype in anaplastic thyroid carcinoma. Int J Exp Pathol 3:755-762, 2010.
23. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene 30:3153-3162, 2011.
24. Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A, Saji M, Ringel MD. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA 20:2803-2808, 2007.
25. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, Goodall GJ. A double negative feedback between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 68:7846-7854, 2008.
26. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR200 family promotes EMT and invasion in cancer cells. EMBO Rep 9:582-589, 2008.
27. Curtis MW, Johnson KR, Wheelock MJ. E-cadherin/catenin complexes are formed co-translationally in the endoplasmic reticulum/Golgi compartments. Cell Commun Adhes 15: 365-378, 2008.
28. Guarino M, Rubino B, Ballabio G. The role of epithelialmesencymal transition in cancer pathology. Pathology 39:305-318, 2007.
29. Matsuo SE, Fiore AP, Siguematu SM, Ebina KN, Frigulietti CU, Ferro MC, Kulcsar MA, Kimura ET. Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues. Arg Bras Endocrinol Metabol 54:406-412, 2010.
30. Ishisaki A, Yamato K, Nakao A, Nonaka K, Ohguchi M, ten Dijke P, Nishihara T. Smad7 is an activin-inhibin inhibitor of activin-induced growth arrest and apopstosis in mouse B cells. J Biol Chem 273:24293-24296, 1998.
31. Halder SK, Beauchamp RD, Datta PK. Smad7 induces tumorigenesis by blocking TGF-beta-induced growth inhibition and apopstosis. Exp Cell Res 307:231-246, 2005.
32. Itoh S, Landstrom M, Hermansson A, Itoh F, Heldin CH, Heldin NE, ten Kijke P. Transforming growth factor beta1 induces nuclear export of inhibitory smad 7. J Biol Chem 273:29195-29201, 1998.
33. Boulay JL, Mild G, Lowy A, Reuter J, Langrange M, Terracciano L, Laffer U, Herrmann R, Rochlitz C. SMAD7 is a prognostic marker in patients with colorectal cancer. Int J cancer 104:446-449, 2003.
34. Dowdy SC, Mariani A, Reinholz MM, Keeney GL, Spelsberg TC, Podratz KC, Janknecht R. Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer. Gynecol Oncol 96:368-373, 2005.
35. Eloy C, Santos J, Cameselle-Teijeiro J, Soares P, Sobrinho-Simoes M. TGF-beta/Smad pathway and RAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma. Virchows Arch 460:587-600, 2012.